ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0003

Assessing Cytokine Profiles and COVID Serology in Patients on Immunosuppression to Guide Care Recommendations
Abstract Number: 1008

Assessing Improved Risk Prediction of Seropositive Rheumatoid Arthritis by Environmental, Genetic, and Preclinical Plasma Metabolite Factors
Abstract Number: 1096

Assessing Interstitial Lung Disease in a Racially Diverse Population with Idiopathic Inflammatory Myositis
Abstract Number: 1612

Assessing Patient Self-Reported Transition Readiness in a Large Pediatric Rheumatology Center
Abstract Number: 1615

Assessing Preparation for Care Transition Among Adolescents with Rheumatologic Disease: A Quality Assessment with Patient Survey
Abstract Number: 1251

Assessing the Construct Validity of the Novel OMERACT Ultrasound Scoring System for Salivary Glands Target Lesions by Comparison with MRI in Patients with Sjögren’s Syndrome – An OMERACT Ultrasound Working Group Exercise
Abstract Number: 1579

Assessing the Effect of Calcineurin Inhibitors for Immune-related Adverse Event Management on Tumor Response
Abstract Number: 1602

Assessing the Psychometric Properties of a Measure of Patient Empowerment with Patients with Arthritis
Abstract Number: 0111

Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic
Abstract Number: 1903

Assessment of Global DNA Methylation in Peripheral Blood Cell Subpopulations of Patients with Axial Spondyloarthritis : Preliminary Results
Abstract Number: 0320

Assessment of Implementation of Treat to Target Concept Using Validated Composite Scores in Psoriatic Arthritis Patients
Abstract Number: 0248

Assessment of Lupus Knowledge Through Creation of the Lupus Knowledge Assessment Test (LKAT)
Abstract Number: 0474

Assessment of Teaching Behavior and Knowledge Among Faculty to Inform an Active Teaching Intervention Within a Rheumatology Fellowship Curriculum
Abstract Number: 1726

Assessment of the Components of RAPID3 Patient Reported Outcomes in an Community Rheumatology Practice
Abstract Number: 0464

Assessment of the COVID-19 Pandemic from the Perspective of People with Rheumatic Musculoskeletal Diseases in Europe. Preliminary Results from the REUMAVID Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].